Drug intelligence / Profile preview

GCB-001

Development stage: Unknown
Lead developer: Genecombio
Modality: Gene Addition/Replacement → Gene Therapies, Gene Editing → Gene Therapies, Gene Silencing → Gene Therapies
Administration: Intrathecal

Overview

GCB-001 is a biological investigational therapy developed by Genecombio Ltd. It is currently being evaluated in clinical studies for the treatment of patients with delayed onset type 2 spinal muscular atrophy (SMA) who can sit alone but cannot walk. The drug is administered as a single intrathecal injection, and ongoing trials are assessing its safety, tolerability, and preliminary efficacy in pediatric patients aged 2–12 years old. The precise mechanism of action and molecular target have not been disclosed publicly as of June 2025[1][2][3].

Targets

MECP2 (Methyl-CpG-binding protein 2)

Beyond the preview

Go deeper on GCB-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GCB-001.

Explore the full profile